EyePoint stock crashed 67% after Duravyu missed its primary endpoint against aflibercept in the LUGANO Phase 3 for wet AMD - with nine vision-loss cases in the treatment arm versus zero. Also: argenx's Vyvgart Hytrulo hits in autoimmune myositis, AstraZeneca scraps its volrustomig bispecific in lung cancer while Enhertu and Tagrisso win, Sandoz signs a $322M biosimilar deal with Shanghai Henlius, Cytokinetics sues Bristol Myers Squibb over aficamten and Camzyos, and Slate Medicines merges with Fulcrum Therapeutics. Visit us at thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →